Overview
- AstraZeneca, which reported results Wednesday, posted $15.3 billion in revenue and core EPS of $2.58, beating analyst estimates on both.
- Oncology sales rose about 16% at constant exchange rates to roughly $6.8 billion, with Imfinzi, Tagrisso, Enhertu and Calquence driving gains.
- The company kept its 2026 guidance for mid‑to‑high single‑digit revenue growth and low double‑digit core EPS growth at constant exchange rates.
- Management flagged four positive Phase 3 results since the prior quarter, including first pivotal data for two new molecular entities, and reported 21 late‑stage NMEs across 186 projects.
- Shares slipped about 1% to 2% in London after the beat, while Citi on Thursday raised its 2026 EPS forecast and kept a buy rating, pointing to second‑half trial catalysts.